Endothelial Cell Dysfunction and Oxidative Stress

Chesley's Hypertensive Disorders in Pregnancy

Volumn , Issue , 2009, Pages 143-167

  Taylor, Robert N ^a   Davidge, Sandra T ^b   Roberts, James M ^c  

^a Gynecology and Obstetrics   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882515566     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374213-1.00009-4     Document Type: Chapter

References (287)

1. J.C.W. Lever (1843) Cases of puerperal convulsions, with remarks. Guys Hosp Rep 1 495-517.
2. A. Mayer (1924) Changes in the endothelium during eclampsia and their significance (translated from German). Klin Wochenzeitschr H27.
3. E.T. Bell (1932) Renal lesions in the toxemias of pregnancy. Am J Pathol 8 1-42.
4. B.H. Spargo, C. Lichtig, A.M. Luger, A.I. Katz and M.D. Lindheimer (1976) The renal lesion in preeclampsia: Examination by light-, electron- and immunofluorescence-microscopy. M.D. Lindheimer, A.I. Katz, F.P. Zuspan (Eds) Hypertension in Pregnancy New York: Wiley
5. H.L. Sheehan and J.B. Lynch (1973) Pathology of Toxaemia of Pregnancy. London: Churchill
6. D.R. Shanklin and B.M. Sibai (1990) Ultrastructural aspects of preeclampsia. II. Mitochondrial changes. Am J Obstet Gynecol 163 943-953.
7. C.J.M. De Groot, D.C. Merrill, R.N. Taylor, J.L. Kitzmiller, P.C. Goldsmith and J.M. Roberts (1997) Increased Von Willebrand factor expression in an experimental model of preeclampsia produced by reduction of uteroplacental perfusion pressure in conscious Rhesus monkeys. Hypertens Pregnancy 16 177-185.
8. M. Grundmann, A. Woywodt, T. Kirsch, et al. (2008) Circulating endothelial cells: a marker of vascular damage in patients with preeclampsia. Am J Obstet Gynecol 198 e1-e5.
9. T.Y. Khong, I.H. Sawyer and A.R. Heryet (1992) An immunohistologic study of endothelialization of uteroplacental vessels in human pregnancy: Evidence that endothelium is focally disrupted by trophoblast in preeclampsia. Am J Obstet Gynecol 167 751-756.
10. Y. Zhou, C.H. Damsky and S.J. Fisher (1997) Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 99 2152-2164.
11. P.M. Zeek and N.S. Assali (1950) Vascular changes in the decidua associated with eclamptogenic toxemia. Am J Clin Pathol 20 1099-1109.
12. P. Nadji and S.C. Sommers (1973) Lesions of toxemia in first trimester pregnancies. Am J Clin Pathol 59 344-348.
13. F. De Wolf, W.B. Robertson and I. Brosens (1975) The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 123 164-174.
14. E.W. Raines and R. Ross (1993) Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69 S30-S37.
15. J.M. Roberts, R.N. Taylor, T.J. Musci, G.M. Rodgers, C.A. Hubel and M.K. Mclaughlin (1989) Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 161 1200-1204.
16. E.A. Jaffe (1987) Cell biology of endothelial cells. Hum Pathol 18 234-239.
17. C.J. De Groot and R.N. Taylor (1993) New insights into the etiology of pre-eclampsia. Ann Med 25 243-249.
18. J.M. Roberts and H.S. Gammill (2005) Preeclampsia: recent insights. Hypertension 46 1243-1249.
19. J.S. Pober and R.S. Cotran (1990) Cytokines and endothelial cell biology. Physiol Rev 70 427-451.
20. R.L. Nachman and R. Silverstein (1993) Hypercoagulable states. Ann Intern Med 119 819-827.
21. R.C. Baxter and J.L. Martin (1986) Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest 78 1504-1512.
22. I.A. Greer, F. Lyall, T. Perera, F. Boswell and L.M. Macara (1994) Increased concentration of cytokines interleukin-6 and imterleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol 84 937-940.
23. R.M. Bukowski (1982) Thrombotic thrombocytopenic purpura: A review. Prog Hemostat Thromb 6 287-337.
24. C.P. Weiner (1987) Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 24 119-129.
25. Y.C. Chen, B. Mcleod, E.R. Hall and K.K. Wu (1981) Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura. Lancet 2 267-269.
26. J.L. Kitzmiller and K. Benirschke (1973) Immunofluorescent study of placental bed vessels in pre-eclampsia of pregnancy. Am J Obstet Gynecol 115 248-251.
27. D.S. Dizon-Townson, L.M. Nelson, K. Easton and K. Ward (1996) The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 175 902-905.
28. C. Lindoff, I. Ingemarsson, G. Martinsson, M. Segelmark, H. Thysell and B. Astedt (1997) Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 176 457-460.
29. G.A. Dekker, J.I. De Vries, P.M. Doelitzsch, et al. (1995) Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173 1042-1048.
30. R.N. Taylor, W.R. Crombleholme, S.A. Friedman, L.A. Jones, D.C. Casal and J.M. Roberts (1991) High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 165 895-901.
31. C.D. Hsu, J.A. Copel, S.F. Hong and D.W. Chan (1995) Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol 86 897-899.
32. A. Estelles, J. Gilabert, F. Espana, J. Aznar and M. Galbis (1991) Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 165 138-142.
33. S.A. Friedman, E. Schiff, J.J. Emeis, G.A. Dekker and B.M. Sibai (1995) Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 172 202-203.
34. M. Gao, M. Nakabayashi, M. Sakura and Y. Takeda (1996) The imbalance of plasminogen activators and inhibitor in preeclampsia. J Obstet Gynaecol Res 22 9-16.
35. A. Kanfer, J.F. Bruch, G. Nguyen, et al. (1996) Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest 74 253-258.
36. M. Shaarawy and H.E. Didy (1996) Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynaecol Obstet 55 135-139.
37. R.O. Hynes (1981) Cell Biology of the Extracellular Matrix. New York: Plenum Press
38. J. Aznar-Salatti, E. Bastida, M.R. Buchanan, R. Castillo, A. Ordinas and G. Escolar (1990) Differential localization of von Willebrand factor, fibronectin and 13-HODE in human endothelial cell cultures. Histochemistry 93 507-511.
39. K.D. Forsyth and R.J. Levinsky (1990) Fibronectin degradation; an in-vitro model of neutrophil mediated endothelial cell damage. J Pathol 161 313-319.
40. J. Lazarchick, T.M. Stubbs, L. Romein, J.P. Van Dorsten and C.B. Loadholt (1986) Predictive value of fibronectin levels in normotensive gravid women destined to become preeclamptic. Am J Obstet Gynecol 154 1050-1052.
41. M. Letowska, K. Bykowska, J. Sablinski, S. Lopaciuk and M. Kopec (1990) Venostasis but not DDAVP infusion provokes the plasma fibronectin increase. Thromb Haemost 64 294-296.
42. S. Ogawa, R. Shreeniwas, C. Butura, J. Brett and D.M. Stern (1990) Modulation of endothelial function by hypoxia: perturbation of barrier and anticoagulant function, and induction of a novel factor X activator. Adv Exp Med Biol 281 303-312.
43. J.H. Peters, L.A. Sporn, M.H. Ginsberg and D.D. Wagner (1990) Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type III homology (ED1). Blood 75 1801-1808.
44. C.J. Lockwood and J.H. Peters (1990) Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 162 358-362.
45. F. Lyall, I.A. Greer, F. Boswell, L.M. Macara, J.J. Walker and J.C. Kingdom (1994) The cell adhesion molecule, VCAM-1, is selectively elevated in serum in pre-eclampsia: does this indicate the mechanism of leucocyte activation? Br J Obstet Gynaecol. 101 485-487.
46. T. Krauss, W. Kuhn, C. Lakoma and H.G. Augustin (1997) Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk of developing preeclampsia. Am J Obstet Gynecol 177 443-449.
47. R.N. Taylor, D.C. Heilbron and J.M. Roberts (1990) Growth factor activity in the blood of women in whom preeclampsia develops is elevated from early pregnancy. Am J Obstet Gynecol 163 1839-1844.
48. R.N. Taylor, T.J. Musci, R.W. Kuhn and J.M. Roberts (1990) Partial characterization of a novel growth factor from the blood of women with preeclampsia. J Clin Endocrinol Metab 70 1285-1291.
49. G.W. Booz and K.M. Baker (1995) Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 30 537-543.
50. M. Varma, C.J.M. De Groot, S. Lanyi and R.N. Taylor (1993) Evaluation of plasma insulin-like growth factor-binding protein-3 as a potential predictor of preeclampsia. Am J Obstet Gynecol 169 995-999.
51. M.S. Lewitt, F.P. Scott, N.M. Clarke and R.C. Baxter (1995) Developmental regulation of circulating insulin-like growth factor-binding proteins in normal pregnancies and in pre-eclampsia. Prog Growth Factor Res 6 475-480.
52. C.J.M. De Groot, T.J. O’Brien and R.N. Taylor (1996) Biochemical evidence of impaired trophoblastic invasion of decidual stroma in women destined to have preeclampsia. Am J Obstet Gynecol 175 24-29.
53. R.J. Howell, D. Economides, B. Teisner, A.G. Farkas and T. Chard (1989) Placental proteins 12 and 14 in pre-eclampsia. Acta Obstet Gynecol Scand 68 237-240.
54. L.C. Giudice, N.A. Martina, R.A. Crystal, S. Tazuke and M. Druzin (1997) Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia. Am J Obstet Gynecol 176 751-757.
55. M. Yanagisawa, H. Kurihara, S. Kimura, et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 411-415.
56. Y. Watanabe, M. Naruse, C. Monzen, et al. (1991) Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol 17 S503-S505.
57. N. Suzuki, H. Matsumoto, C. Kitada, T. Masaki and M. Fujino (1989) A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods 118 245-250.
58. M. Molnár and F. Hertelendy (1990) Pressor responsiveness to endothelin is not attenuated in gravid rats. Life Sci 47 1463-1468.
59. G. Bodelsson, N.O. Sjoberg and M. Stjernquist (1992) Contractile effect of endothelin in the human uterine artery and autoradiographic localization of its binding sites. Am J Obstet Gynecol 167 745-750.
60. G. Remuzzi and A. Benigni (1993) Endothelins in the control of cardiovascular and renal function. Lancet 342 589-593.
61. S.J. Kilpatrick, J.M. Roberts, D.L. Lykins and R.N. Taylor (1993) Characterization and ontogeny of endothelin receptors in human placenta. Am J Physiol 264 E367-E372.
62. R.N. Taylor, M. Varma, N.N.H. Teng and J.M. Roberts (1990) Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 71 1675-1677.
63. A. Nova, B.M. Sibai, J.R. Barton, B.M. Mercer and M.D. Mitchell (1991) Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 165 724-727.
64. Mastrogiannis Ds, W.F. O’brien, J. Krammer and R. Benoit (1991) Potential role of endothelin-1 in normal and hypertensive pregnancies. Am J Obstet Gynecol 165 1711-1716.
65. A. Benigni, S. Orisio, F. Gaspari, T. Frusca, G. Amuso and G. Remuzzi (1992) Evidence against a pathogenetic role for endothelin in pre-eclampsia. Br J Obstet Gynaecol 99 798-802.
66. S. Ahlawat, H.P. Pati, N. Bhatla, L. Fatima and S. Mittal (1996) Plasma platelet aggregating factor and platelet aggregation studies in pre-eclampsia. Acta Obstet Gynecol Scand 75 428-431.
67. W. Klockenbusch, T. Hohlfeld, M. Wilhelm, T. Somville and K. Schror (1996) Platelet PGI2 receptor affinity is reduced in pre-eclampsia. Br J Clin Pharmacol 41 616-618.
68. R.A. North, C. Ferrier, G. Gamble, K.F. Fairley and P. Kincaid-Smith (1995) Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 35 357-362.
69. J.C. Hauth, R.L. Goldenberg, C.J. Parker, et al. (1993) Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 168 1083-1091.
70. B.M. Sibai, S.N. Caritis, E. Thom, et al. (1993) Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Eng J Med 329 1213-1218.
71. CLASP (1994) A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 343 619-629.
72. L.M. Askie, L. Duley, D.J. Henderson-Smart and L.A. Stewart (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369 1791-1798.
73. J.M. Roberts and J.M. Catov (2007) Aspirin for pre-eclampsia: compelling data on benefit and risk. Lancet 369 1765-1766.
74. G.A. Dekker and H.P. Van Geijn (1996) Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. J Perinat Med 24 99-117.
75. C. Lees, E. Langford, A.S. Brown, et al. (1996) The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 88 14-19.
76. A. Halim, N. Kanayama, E. El Maradny, K. Maehara, A.B. Bhuiyan and T. Terao (1996) Correlated plasma elastase and sera cytotoxicity in eclampsia. A possible role of endothelin-1 induced neutrophil activation in preeclampsia-eclampsia. Am J Hypertens 9 33-38.
77. I. Rebelo, F. Carvalho-Guerra, L. Pereira-Leite and A. Quintanilha (1996) Comparative study of lactoferrin and other blood markers of inflammatory stress between preeclamptic and normal pregnancies. Eur J Obstet Gynecol Reprod Biol 64 167-173.
78. A. Barden, D. Graham, L.J. Beilin, et al. (1997) Neutrophil CD11b expression and neutrophil activation in pre-eclampsia. Clin Sci 92 37-44.
79. K. Studena, G.P. Sacks, I.L. Sargent and C.W.G. Redman (1997) Leucocyte phenotypic and functional changes in preeclampsia and normal pregnancy. Combined detection by whole blood flow cytometry. J Soc Gynecol Invest 4(Suppl.), 664. [abst.]
80. C.W. Redman and I.L. Sargent (2005) Latest advances in understanding preeclampsia. Science 308 1592-1594.
81. C.M. Salafia, A. Ghidini and V.K. Minior (1996) Uterine allergy: a cause of preterm birth? Obstet Gynecol 88 451-454.
82. A.K. Smarason, I.L. Sargent and C.W.G. Redman (1996) Endothelial cell proliferation is suppressed by plasma but not serum from women with preeclampsia. Am J Obstet Gynecol 174 787-793.
83. A.P. Cockell, J.G. Learmont, A.K. Smarason, C.W. Redman, I.L. Sargent and L. Poston (1997) Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol 104 235-240.
84. C.W. Redman and I.L. Sargent (2008) Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 29(Suppl A), S73-S77.
85. B.M. Sibai, T. Gordon, E. Thom, et al. (1995) Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 172 642-648.
86. M.T. Houser, A.J. Fish, G.E. Tagatz, P.P. Williams and A.F. Michael (1980) Pregnancy and systemic lupus erythematosus. Am J Obstet Gynecol 138 409-413.
87. I.A. Brosens, W.B. Robertson and H.G. Dixon (1972) The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1 177-191.
88. P.Y. Robillard, G. Dekker, G. Chaouat and T.C. Hulsey (2007) Etiology of preeclampsia: maternal vascular predisposition and couple disease – mutual exclusion or complementarity? J Reprod Immunol 76 1-7.
89. P.Y. Robillard, T.C. Hulsey, G.R. Alexander, A. Keenan, F. De Caunes and E. Papiernik (1993) Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol 24 1-12.
90. H.S. Klonoff-Cohen, D.A. Savitz, R.C. Cefalo and M.F. Mccann (1989) An epidemiologic study of contraception and preeclampsia. JAMA 262 3143-3147.
91. V. Soderstrom-Anttila and O. Hovatta (1995) An oocyte donation program with goserelin down-regulation of voluntary donors. Acta Obstet Gynecol Scand 74 288-292.
92. J.G. Feeney, L.A. Tovey and J.S. Scott (1977) Influence of previous blood-transfusion on incidence of pre-eclampsia. Lancet 1 874-875.
93. C.A. Koelman, A.B. Coumans, H.W. Nijman, I.I. Doxiadis, G.A. Dekker and F.H. Claas (2000) Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol 46 155-166.
94. P.Y. Robillard, T.C. Hulsey, J. Perianin, E. Janky, E.H. Miri and E. Papiernik (1994) Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 344 973-975.
95. R.N. Taylor (1997) Review: Immunobiology of preeclampsia. Am J Reprod Immunol 37 79-86.
96. J.Y. Allen, C. Tapia-Santiago and W.H. Kutteh (1996) Antiphospholipid antibodies in patients with preeclampsia. Am J Reprod Immunol 36 81-85.
97. M. Shaarawy, S.Y. El-Mallah and A.M.A. El-Yamani (1997) The prevalence of serum antineutrophil cytoplasmic autoantibodies in preeclampsia and eclampsia. J Soc Gynecol Invest 4 34-39.
98. K. Katano, A. Aoki, H. Sasa, M. Ogasawara, E. Matsuura and Y. Yagami (1996) Beta 2-glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 11 509-512.
99. G.M. Rodgers, R.N. Taylor and J.M. Roberts (1988) Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 159 908-914.
100. V.J. Rappaport, G. Hirata, H.K. Yap and S.C. Jordan (1990) Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 162 138-146.
101. S.H. Tannenbaum, R. Finko and D.B. Cines (1986) Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137 1532-1537.
102. C.J. De Groot, S.T. Davidge, S.A. Friedman, M.K. Mclaughlin, J.M. Roberts and R.N. Taylor (1995) Plasma from preeclamptic women increases human endothelial cell prostacyclin production without changes in cellular enzyme activity or mass. Am J Obstet Gynecol 172 976-985.
103. D.W. Branch, D.J. Dudley, S. Lamarche and M.D. Mitchell (1992) Sera from preeclamptic patients contain factor(s) that stimulate prostacyclin production by human endothelial cells. Prostaglandins Leukot Essent Fatty Acids 45 191-195.
104. C.J.M. De Groot, J.T. Murai, J.-L. Vigne and R.N. Taylor (1998) Eicosanoid secretion by human endothelial cells exposed to normal pregnancy and preeclampsia plasma in vitro. Prostaglandins Leukot Essent Fatty Acids 58 91-97.
105. N.S. Rote, A. Walter and T.W. Lyden (1992) Antiphospholipid antibodies – lobsters or red herrings? Am J Reprod Immunol 28 31-37.
106. R. Dechend, V. Homuth, G. Wallukat, et al. (2006) Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Invest 13 79-86.
107. A.M. Peaceman and K.A. Rehnberg (1995) The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Am J Obstet Gynecol 173 1391-1396.
108. Y. Hamai, T. Fujii, T. Yamashita, et al. (1997) Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol 38 89-93.
109. M.A. Williams, A. Farrand, R. Mittendorf, et al. (1999) Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 149 323-329.
110. M.J. Kupferminc, T.A. Mullen, T.L. Russell and R.K. Silver (1996) Serum from patients with severe preeclampsia is not cytotoxic to endothelial cells. J Soc Gynecol Invest 3 89-92.
111. B.K. Rinehart, D.A. Terrone, S. Lagoo-Deenadayalan, et al. (1999) Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 181 915-920.
112. D.F. Benyo, A. Smarason, C.W. Redman, C. Sims and K.P. Conrad (2001) Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 86 2505-2512.
113. M. Yoshizumi, M.A. Perrella, J.C. Burnett Jr. and M.E. Lee (1993) Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 73 205-209.
114. P.A. Marsden and B.M. Brenner (1992) Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 262 C854-C861.
115. J.M. Stark (1993) Pre-eclampsia and cytokine induced oxidative stress. Br J Obstet Gynaecol 100 105-109.
116. J.S. Pober, M.A. Gimbrone Jr., L.A. Lapierre, et al. (1986) Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 137 1893-1896.
117. M.P. Bevilacqua, J.S. Pober, G.R. Majeau, R.S. Cotran and M.A. Gimbrone Jr. (1984) Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160 618-623.
118. P.P. Nawroth and D.M. Stern (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163 740-745.
119. V.W. Van Hinsbergh, T. Kooistra, E.A. Van Den Berg, H.M. Princen, W. Fiers and J.J. Emeis (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72 1467-1473.
120. B.T. Alexander, K.L. Cockrell, M.B. Massey, W.A. Bennett and J.P. Granger (2002) Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens 15 170-175.
121. J.B. Giardina, G.M. Green, K.L. Cockrell, J.P. Granger and R.A. Khalil (2002) TNF-alpha enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol 283 R130-R143.
122. E.S. Vizi, J. Szelenyi, Z.S. Selmeczy, Z. Papp, Z.H. Nemeth and G. Hasko (2001) Enhanced tumor necrosis factor-alpha-specific and decreased interleukin-10-specific immune responses to LPS during the third trimester of pregnancy in mice. J Endocrinol 171 355-361.
123. P.B. Jacobson and D.J. Schrier (1993) Regulation of CD11b/CD18 expression in human neutrophils by phospholipase A2. J Immunol 151 5639-5652.
124. J. Pfeilschifter, C. Schalkwijk, V.A. Briner and H. van den Bosch (1993) Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest 92 2516-2523.
125. A. Jendryczko and M. Drózdz (1990) Increased placental phospholipase A2 activities in pre-eclampsia. Zentralbl Gynakol 112 889-891.
126. K.H. Lim, G.E. Rice, C.J. Degroot and R.N. Taylor (1995) Plasma type II phospholipase A2 levels are elevated in severe preeclampsia. Am J Obstet Gynecol 172 998-1002.
127. S.L. Opsjon, D. Novick, N.C. Wathen, A.P. Cope, D. Wallach and D. Aderka (1995) Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies. J Reprod Immunol 29 119-134.
128. G.S. Vince, P.M. Starkey, R. Austgulen, D. Kwiatkowski and C.W. Redman (1995) Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 102 20-25.
129. C.G. Domingo, N. Domenech, P. Aparicio and P. Palomino (1985) Human pregnancy serum inhibits proliferation of T8-depleted cells and their interleukin-2 synthesis in mixed lymphocyte cultures. J Reprod Immunol 8 97-110.
130. N. Hara, T. Fujii, T. Okai and Y. Taketani (1995) Histochemical demonstration of interleukin-2 in decidua cells of patients with preeclampsia. Am J Reprod Immunol 34 44-51.
131. R. Raghupathy and J. Kalinka (2008) Cytokine imbalance in pregnancy complications and its modulation. Front Biosci 13 985-994.
132. T. Stallmach, G. Hebisch, H. Joller, P. Kolditz and M. Engelmann (1995) Expression pattern of cytokines in the different compartments of the feto-maternal unit under various conditions. Reprod Fertil Dev 7 1573-1580.
133. B.W. Arbogast, S.C. Leeper, R.D. Merrick, K.E. Olive and R.N. Taylor (1994) Which plasma factors bring about disturbance of endothelial function in pre-eclampsia? Lancet 343 340-341.
134. M.J. Endresen, E. Tosti, H. Heimli, B. Lorentzen and T. Henriksen (1994) Effects of free fatty acids found increased in women who develop pre-eclampsia on the ability of endothelial cells to produce prostacyclin, cGMP and inhibit platelet aggregation. Scand J Clin Lab Invest 54 549-557.
135. G.A. Dekker and H.P. Van geijn (1996) Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. J Perinat Med 24 119-139.
136. H. Husby, B. Roald, R. Schjetlein, B.I. Nesheim and K. Berg (1996) High levels of Lp(a) lipoprotein in a family with cases of severe pre-eclampsia. Clin Genet 50 47-49.
137. A. Wakatsuki, N. Ikenoue, Y. Okatani, K. Shinohara and T. Fukaya (2000) Lipoprotein particles in preeclampsia: susceptibility to oxidative modification. Obstet Gynecol 96 55-59.
138. J.M. Potter and P.J. Nestel (1979) The hyperlipidemia of pregnancy in normal and complicated pregnancies. Am J Obstet Gynecol 133 165-170.
139. C.A. Hubel (1998) Dyslipidemia, iron, and oxidative stress in preeclampsia: assessment of maternal and feto-placental interactions. Semin Reprod Endocrinol 16 75-92.
140. C.A. Hubel, M.K. Mclaughlin, R.W. Evans, B.A. Hauth, C.J. Sims and J.M. Roberts (1996) Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48hours post partum. Am J Obstet Gynecol 174 975-982.
141. C.A. Hubel, F. Lyall, L. Weissfeld, R.E. Gandley and J.M. Roberts (1998) Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism 47 1281-1288.
142. J.L. Witztum (1993) Susceptibility of low-density lipoprotein to oxidative modification. Am J Med 94 347-349.
143. V. Anber, B.A. Griffin, M. Mcconnell, C.J. Packard and J. Shepherd (1996) Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124 261-271.
144. N. Sattar, A. Bendomir, C. Berry, J. Shepherd, I.A. Greer and C.J. Packard (1997) Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol 89 403-408.
145. M.T. Raijmakers, B.J. Van Tits, H.L. Hak-Lemmers, E.M. Roes, E.A. Steegers and W.H. Peters (2004) Low plasma levels of oxidized low density lipoprotein in preeclampsia. Acta Obstet Gynecol Scand 83 1173-1177.
146. D.W. Branch, M.D. Mitchell, E. Miller, W. Palinski and J.L. Witztum (1994) Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 343 645-646.
147. J. Uotila, T. Solakivi, O. Jaakkola, R. Tuimala and T. Lehtimaki (1998) Antibodies against copper-oxidised and malondialdehyde-modified low density lipoproteins in pre-eclampsia pregnancies. Br J Obstet Gynaecol 105 1113-1117.
148. E. Gratacos, E. Casals, R. Deulofeu, et al. (2001) Serum antibodies to oxidized low-density lipoprotein in pregnant women with preeclampsia and chronic hypertension: lack of correlation with lipid peroxides. Hypertens Pregnancy 20 177-183.
149. V.W. Armstrong, E. Wieland, F. Diedrich, et al. (1994) Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease. Lancet 343 1570.
150. T. Sawamura, N. Kume, T. Aoyama, et al. (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature 386 73-77.
151. Y. Yamada, T. Doi, T. Hamakubo and T. Kodama (1998) Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 54 628-640.
152. L. Cominacini, A. Rigoni, A.F. Pasini, et al. (2001) The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276 13750-13755.
153. O. Hofnagel, B. Luechtenborg, K. Stolle, et al. (2004) Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24 1789-1795.
154. H. Morawietz, U. Rueckschloss, B. Niemann, et al. (1999) Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100 899-902.
155. H. Morawietz, N. Duerrschmidt, B. Niemann, J. Galle, T. Sawamura and J. Holtz (2002) Augmented endothelial uptake of oxidized low-density lipoprotein in response to endothelin-1. Clin Sci (Lond) 103(Suppl 48), 9S-12S.
156. B.T. Alexander, M.T. Llinas, W.C. Kruckeberg and J.P. Granger (2004) L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 43 832-836.
157. B. Halvorsen, A.C. Staff, T. Henriksen, T. Sawamura and T. Ranheim (2001) 8-iso-prostaglandin F(2alpha) increases expression of LOX-1 in JAR cells. Hypertension 37 1184-1190.
158. M. Muy-Rivera, S.E. Sanchez, S. Vadachkoria, C. Qiu, V. Bazul and M.A. Williams (2004) Transforming growth factor-beta1 (TGF-beta1) in plasma is associated with preeclampsia risk in Peruvian women with systemic inflammation. Am J Hypertens 17 334-338.
159. S. Sankaralingam, I.A. Arenas, M.M. Lalu and S.T. Davidge (2006) Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 8 1-20.
160. B. Lorentzen, C.A. Drevon, M.J. Endresen and T. Henriksen (1995) Fatty acid pattern of esterified and free fatty acids in sera of women with normal and pre-eclamptic pregnancy. Br J Obstet Gynaecol 102 530-537.
161. B. Arbogast, S. Leeper, R. Merrick, K. Olive and R. Taylor (1996) Plasma factors that determine endothelial cell lipid toxicity in vitro correctly identify women with preeclampsia in early and late pregnancy. Hypertens Pregnancy 15 263-279.
162. J.-L. Vigne, J.T. Murai, B.W. Arbogast, W. Jia, S.J. Fisher and R.N. Taylor (1997) Elevated non-esterified fatty acid concentrations in severe preeclampsia shift the isoelectric characteristics of plasma albumin. J Clin Endocrinol Metab 82 3786-3792.
163. G.A. Dekker and B.M. Sibai (1998) Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179 1359-1375.
164. M.J. Endresen, B. Lorentzen and T. Henriksen (1992) Increased lipolytic activity and high ratio of free fatty acids to albumin in sera from women with preeclampsia leads to triglyceride accumulation in cultured endothelial cells. Am J Obstet Gynecol 167 440-447.
165. Y.A. Gryzunov, A. Arroyo, J.L. Vigne, et al. (2003) Binding of fatty acids facilitates oxidation of cysteine-34 and converts copper-albumin complexes from antioxidants to prooxidants. Arch Biochem Biophys 413 53-66.
166. R.E. Gandley, V.A. Tyurin, W. Huang, et al. (2005) S-nitrosoalbumin-mediated relaxation is enhanced by ascorbate and copper: effects in pregnancy and preeclampsia plasma. Hypertension 45 21-27.
167. V.E. Kagan, V.A. Tyurin, G.G. Borisenko, et al. (2001) Mishandling of copper by albumin: role in redox-cycling and oxidative stress in preeclampsia plasma. Hypertens Pregnancy 20 221-241.
168. V.A. Tyurin, S.X. Liu, Y.Y. Tyurina, et al. (2001) Elevated levels of S-nitrosoalbumin in preeclampsia plasma. Circ Res 88 1210-1215.
169. Y. Barak, M.C. Nelson, E.S. Ong, et al. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4 585-595.
170. S. Kersten, B. Desvergne and W. Wahli (2000) Roles of PPARs in health and disease. Nature 405 421-424.
171. W.T. Schaiff, Y. Barak and Y. Sadovsky (2006) The pleiotropic function of PPAR gamma in the placenta. Mol Cell Endocrinol 249 10-15.
172. T. Fournier, V. Tsatsaris, K. Handschuh and D. Evain-Brion (2007) PPARs and the placenta. Placenta 28 65-76.
173. Wieser F, Waite L, Depoix C, Taylor RN. PPAR action in human placental development and pregnancy and its complications. PPAR Research, Article ID 527048 2008: 14 pages, doi:10.1155/2008/527048.
174. L.L. Waite, A.K. Atwood and R.N. Taylor (2002) Preeclampsia, an implantation disorder. Rev Endocr Metab Disord 3 151-158.
175. L.L. Waite, R.E. Louie and R.N. Taylor (2005) Circulating activators of peroxisome proliferator-activated receptors are reduced in preeclamptic pregnancy. J Clin Endocrinol Metab 90 620-626.
176. C.W. Redman and I.L. Sargent (2003) Pre-eclampsia, the placenta and the maternal systemic inflammatory response – a review. Placenta 24(Suppl A), S21-S27.
177. I. Barroso, M. Gurnell, V.E. Crowley, et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 880-883.
178. J. Laasanen, S. Heinonen, M. Hiltunen, A. Mannermaa and M. Laakso (2002) Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with preeclampsia. Early Hum Dev 69 77-82.
179. N. Vaisman, D. Gospodarowicz and G. Neufeld (1990) Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265 19461-19466.
180. T.P. Quinn, Peters Kg, C. De Vries, N. Ferrara and L.T. Williams (1993) Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A 90 7533-7537.
181. J. Brockelsby, R. Hayman, A. Ahmed, A. Warren, I. Johnson and P. Baker (1999) VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia. Lab Invest 79 1101-1111.
182. I. Kim, S.O. Moon, S.H. Kim, H.J. Kim, Y.S. Koh and G.Y. Koh (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276 7614-7620.
183. R.N. Taylor, J. Grimwood, R.S. Taylor, M.T. Mcmaster, S.J. Fisher and R.A. North (2003) Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 188 177-182.
184. R.J. Levine, S.E. Maynard, C. Qian, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Eng J Med 350 672-683.
185. W. Jelkmann (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47 617-623.
186. T.A. Molskness, R.L. Stouffer, K.A. Burry, M.J. Gorrill, D.M. Lee and P.E. Patton (2004) Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 19 822-830.
187. H. Hurwitz and S. Saini (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33 S26-S34.
188. D. Clark, S. Smith, D. Licence, A. Evans and D. Charnock-Jones (1998) Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 159 459-467.
189. M. Shibuya (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26 25-35.
190. P. Vuorela, S. Helske, C. Hornig, K. Alitalo, H. Weich and E. Halmesmaki (2000) Amniotic fluid – soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 95 353-357.
191. S.E. Maynard, J.Y. Min, J. Merchan, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 649-658.
192. Y. Gu, D.F. Lewis and Y. Wang (2008) Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 93 260-266.
193. R.J. Levine, R. Thadhani, C. Qian, et al. (2005) Urinary placental growth factor and risk of preeclampsia. JAMA 293 77-85.
194. A. De Vivo, G. Baviera, D. Giordano, G. Todarello, F. Corrado and R. D’anna (2008) Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87 837-842.
195. D. Hanahan (1997) Signaling vascular morphogenesis and maintenance. Science 277 48-50.
196. R.N. Taylor, T.J. Musci, G.M. Rodgers and J.M. Roberts (1991) Preeclamptic sera stimulate increased platelet-derived growth factor mRNA and protein expression by cultured human endothelial cells. Am J Reprod Immunol 25 105-108.
197. F. Lebrin, M. Deckers, P. Bertolino and P. Ten Dijke (2005) TGF-beta receptor function in the endothelium. Cardiovasc Res 65 599-608.
198. A.C. Staff, K. Braekke, G.M. Johnsen, S.A. Karumanchi and N.K. Harsem (2007) Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 197 e1-e6.
199. R. Visse and H. Nagase (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 827-839.
200. C. Fernandez-Patron, K.G. Stewart, Y. Zhang, E. Koivunen, M.W. Radomski and S.T. Davidge (2000) Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 670-676.
201. Z.S. Galis and J.J. Khatri (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 251-262.
202. C. Fernandez-Patron, M.W. Radomski and S.T. Davidge (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 906-911.
203. G. Sawicki, E. Salas, J. Murat, H. Miszta-Lane and M.W. Radomski (1997) Release of gelatinase A during platelet activation mediates aggregation. Nature 386 616-619.
204. H. Narumiya, Y. Zhang, C. Fernandez-Patron, L.J. Guilbert and S.T. Davidge (2001) Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 20 185-194.
205. J.E. Myers, S.J. Merchant, M. Macleod, G.J. Mires, P.N. Baker and S.T. Davidge (2005) MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 24 103-115.
206. M. Kolben, A. Lopens, J. Blaser, et al. (1996) Proteases and their inhibitors are indicative in gestational disease. Eur J Obstet Gynecol Reprod Biol 68 59-65.
207. S.J. Merchant and S.T. Davidge (2004) The role of matrix metalloproteinases in vascular function: implications for normal pregnancy and pre-eclampsia. BJOG 111 931-939.
208. F. Robbesyn, N. Auge, C. Vindis, et al. (2005) High-density lipoproteins prevent the oxidized low-density lipoprotein-induced endothelial growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 25 1206-1212.
209. S. Rajagopalan, S. Kurz, T. Munzel, et al. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97 1916-1923.
210. T. Okamoto, T. Akaike, T. Sawa, Y. Miyamoto, A. Van Der Vliet and H. Maeda (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276 29596-29602.
211. A. Martinez, H.R. Oh, E.J. Unsworth, et al. (2004) Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383 413-418.
212. E. Schiff, S.A. Friedman, B.M. Sibai, L. Kao and S. Schifter (1995) Plasma and placental calcitonin gene-related peptide in pregnancies complicated by severe preeclampsia. Am J Obstet Gynecol 173 1405-1409.
213. T. Minegishi, M. Nakamura, K. Abe, et al. (1999) Adrenomedullin and atrial natriuretic peptide concentrations in normal pregnancy and pre-eclampsia. Mol Hum Reprod 5 767-770.
214. L. Hao, M. Du, A. Lopez-Campistrous and C. Fernandez-Patron (2004) Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94 68-76.
215. D.K. Chew, M.S. Conte and R.A. Khalil (2004) Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg 40 1001-1010.
216. A. Jeyabalan, J. Novak, L.A. Danielson, L.J. Kerchner, S.L. Opett and K.P. Conrad (2003) Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93 1249-1257.
217. A. Jeyabalan, S.G. Shroff, J. Novak and K.P. Conrad (2007) The vascular actions of relaxin. Adv Exp Med Biol 612 65-87.
218. M. Hanssens, M.J. Keirse, B. Spitz and F.A. Van Assche (1991) Angiotensin II levels in hypertensive and normotensive pregnancies. Br J Obstet Gynaecol 98 155-161.
219. D. Weiss, D. Sorescu and W.R. Taylor (2001) Angiotensin II and atherosclerosis. Am J Cardiol 87 25C-32C.
220. I.A. Arenas, Y. Xu, P. Lopez-Jaramillo and S.T. Davidge (2004) TNFalpha mediates angiotensin II-induced MMP-2 release from endothelial cells. Am J Physiol 286 779-784.
221. M.A. Pawlak and G.J. Macdonald (1992) Altered number of platelet angiotensin II receptors in relation to plasma agonist concentrations in normal and hypertensive pregnancy. J Hypertens 10 813-819.
222. S. Abdalla, H. Lother and U. Quitterer (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 94-98.
223. S. Abdalla, H. Lother, A. El Massiery and U. Quitterer (2001) Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7 1003-1009.
224. N.F. Gant, G.L. Daley, S. Chand, P.J. Whalley and P.C. Macdonald (1973) A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 52 2682-2689.
225. S.M. Bobst, M.C. Day, L.C. Gilstrap 3rd, Y. Xia and R.E. Kellems (2005) Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens 18 330-336.
226. T.M. Thway, S.G. Shlykov, M.C. Day, et al. (2004) Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 110 1612-1619.
227. Y. Xia, H. Wen, S. Bobst, M.C. Day and R.E. Kellems (2003) Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Invest 10 82-93.
228. Y. Xia, C.C. Zhou, S.M. Ramin and R.E. Kellems (2007) Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol 179 3391-3395.
229. F. Herse, A.C. Staff, L. Hering, D.N. Muller, F.C. Luft and R. Dechend (2008) AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med 86 697-703.
230. R. Dechend, P. Gratze, G. Wallukat, et al. (2005) Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 45 742-746.
231. K. Koga and G. Mor (2008) Expression and function of toll-like receptors at the maternal-fetal interface. Reprod Sci 15 231-242.
232. M. Jurk, B. Schulte, A. Kritzler, et al. (2004) C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology 209 141-154.
233. X.Y. Zhong, W. Holzgreve and S. Hahn (2002) The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 21 77-83.
234. E. Difederico, O. Genbacev and S.J. Fisher (1999) Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol 155 293-301.
235. M.A. Gama-Sosa, R.Y. Wang, K.C. Kuo, C.W. Gehrke and M. Ehrlich (1983) The 5-methylcytosine content of highly repeated sequences in human DNA. Nucleic Acids Res 11 3087-3095.
236. M. Grisham and J. Mccord (1986) Chemistry and cytotoxicity of reactive oxygen metabolites. A.E. Taylor, S. Matalon, P. Ward (Eds) Physiology of Oxygen Radicals Bethesda, MD: American Physiological Society 1-19.
237. G.M. Rubanyi (1988) Vascular effects of oxygen-derived free radicals. Free Radic Biol Med 4 107-120.
238. S. Pou, W.S. Pou, D.S. Bredt, S.H. Snyder and G.M. Rosen (1992) Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 267 24173-24176.
239. D.A. Parks and D.N. Granger (1986) Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl 548 87-99.
240. K. Tsukimori, H. Maeda, K. Ishida, H. Nagata, T. Koyanagi and H. Nakano (1993) The superoxide generation of neutrophils in normal and preeclamptic pregnancies. Obstet Gynecol 81 536-540.
241. R.J. Zimmerman, A. Chan and S.A. Leadon (1989) Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 49 1644-1648.
242. C. Maziere, M. Auclair and J. Maziere (1994) Tumour necrosis factor enhances low density protein oxidative modification by monocytes and endothelial cells. FEBS Lett 338 43-46.
243. S. Tan, Y. Yokoyama, E. Dickens, T.G. Cash, B.A. Freeman and D.A. Parks (1993) Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic Biol Med 15 407-414.
244. A. Many, C.A. Hubel and J.M. Roberts (1996) Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol 174 288-291.
245. T. Heitzer, U. Wenzel, U. Hink, et al. (1999) Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int 55 252-260.
246. J.W. Meyer and M.E. Schmitt (2000) A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett 472 1-4.
247. C.A. Hubel, J.M. Roberts, R.N. Taylor, T.J. Musci, G.M. Rogers and M.K. Mclaughlin (1989) Lipid peroxidation in pregnancy: New perspectives on preeclampsia. Am J Obstet Gynecol 161 1025-1034.
248. S.T. Davidge, C.A. Hubel, R.D. Brayden, E.C. Capeless and M.K. Mclaughlin (1992) Sera antioxidant activity in uncomplicated and preeclamptic pregnancies. Obstet Gynecol 79 879-901.
249. C.L. Regan, R.J. Levine, D.D. Baird, et al. (2001) No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol 185 572-578.
250. E. Llurba, E. Gratacos, P. Martin-Gallan, L. Cabero and C. Dominguez (2004) A comprehensive study of oxidative stress and antioxidant status in preeclampsia and normal pregnancy. Free Radic Biol Med 37 557-570.
251. A.R. Rumbold, C.A. Crowther, R.R. Haslam, G.A. Dekker and J.S. Robinson (2006) Vitamins C and E and the risks of preeclampsia and perinatal complications. N Eng J Med 354 1796-1806.
252. J.P.M. Villar, M. Merialdi, N. Zavaleta, N.N. Tien and J. Anthony (2008) WHO randomized trial of vitamin C and E supplementation among women at high risk for preeclamsia and nutritional deficiency. Am J Obstet Gynecol 197.
253. L. Poston, A.L. Briley, P.T. Seed, F.J. Kelly and A.H. Shennan (2006) Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367 1145-1154.
254. W.L. Smith and L.J. Marnett (1991) Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1083 1-17.
255. S.T. Davidge, C.A. Hubel and M.K. McLaughlin (1993) Cyclooxygenase-dependent vasoconstrictor alters vascular function in the vitamin E-deprived rat. Circ Res 73 79-88.
256. S.T. Davidge, W.V. Everson, V.M. Parisi and M.K. McLaughlin (1993) Pregnancy and lipid peroxide-induced alterations of eicosanoid-metabolizing enzymes in the aorta of the rat. Am J Obstet Gynecol 169 1338-1344.
257. A.L. McCarthy, R.G. Woolfson, S.K. Raju and L. Poston (1993) Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol 168 1323-1330.
258. G.A. Knock and L. Poston (1996) Bradykinin-mediated relaxation of isolated maternal resistance arteries in normal pregnancy and preeclampsia. Am J Obstet Gynecol 175 1668-1674.
259. S.W. Walsh (1985) Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol 152 335-340.
260. D.J. Fitzgerald, S.S. Entman, K. Mulloy and G.A. Fitzgerald (1987) Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation 75 956-963.
261. K. Satoh, H. Seki and H. Sakamoto (1991) Role of prostaglandins in pregnancy-induced hypertension. Am J Kidney Dis 17 133-138.
262. J.A. Wang, E.Z. Zhen, Z.Z. Guo and Y.C. Lu (1989) Effect of hyperlipidemic serum on lipid peroxidation, synthesis of prostacyclin and thromboxane by cultured endothelial cells: protective effect of antioxidants. Free Radic Biol Med 7 243-249.
263. P.N. Baker, S.T. Davidge, J. Barankiewicz and J.M. Roberts (1996) Plasma of preeclamptic women stimulates and then inhibits endothelial prostacyclin. Hypertension 27 56-61.
264. L.J. Ignarro (1990) Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16 477-483.
265. T. Nobunaga, Y. Tokugawa, K. Hashimoto, et al. (1996) Plasma nitric oxide levels in pregnant patients with preeclampsia and essential hypertension. Gynecol Obstet Invest 41 189-193.
266. S.P. Seligman, J.P. Buyon, R.M. Clancy, B.K. Young and S.B. Abramson (1994) The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 171 944-948.
267. S.T. Davidge, C.P. Stranko and J.M. Roberts (1996) Urine but not plasma nitric oxide metabolites are decreased in women with preeclampsia. Am J Obstet Gynecol 174 1008-1013.
268. H. Li, C.J. Meininger, J.R. Hawker Jr., et al. (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280 E75-82.
269. D.E. Berkowitz, R. White, D. Li, et al. (2003) Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108 2000-2006.
270. B. Heinzel, M. John, P. Klatt, E. Bohme and B. Mayer (1992) Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 281(Pt 3), 627-630.
271. M. Noris, M. Todeschini, P. Cassis, et al. (2004) L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 43 614-622.
272. P.N. Baker, S.T. Davidge and J.M. Roberts (1995) Plasma from women with preeclampsia increases endothelial cell nitric oxide production. Hypertension 26 244-248.
273. S.T. Davidge, P.N. Baker and J.M. Roberts (1995) NOS expression is increased in endothelial cells exposed to plasma from women with preeclampsia. Am J Physiol 269 1106-1112.
274. A.M. Roggensack, Y. Zhang and S.T. Davidge (1999) Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 33 83-89.
275. J.S. Beckman and W.H. Koppenol (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 C1424-C1437.
276. L. Myatt, R.B. Rosenfield, A.L. Eis, D.E. Brockman, I. Greer and F. Lyall (1996) Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension 28 488-493.
277. S. Pfeiffer, Gorren ACf, K. Schmidt, et al. (1997) Metabolic fate of peroxynitrite in aqueous solution. Reaction with nitric oxide and pH-dependent decomposition to nitrite and oxygen in a 2:1 stoichiometry. J Biol Chem 272 3465-3470.
278. R.E. Huie and S. Padmaja (1993) The reaction of NO with superoxide. Free Radic Res Commun 18 195-199.
279. C.L. Cooke and S.T. Davidge (2002) Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 282 C395-C402.
280. J.C. Gillham, L.C. Kenny and P.N. Baker (2003) An overview of endothelium-derived hyperpolarising factor (EDHF) in normal and compromised pregnancies. Eur J Obstet Gynecol Reprod Biol 109 2-7.
281. R. Busse, G. Edwards, M. Feletou, I. Fleming, P.M. Vanhoutte and A.H. Weston (2002) EDHF: bringing the concepts together. Trends Pharmacol Sci 23 374-380.
282. N.N. Lang, L. Luksha, D.E. Newby and K. Kublickiene (2007) Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women. Am J Physiol Heart Circ Physiol 292 H1026-H1032.
283. L. Luksha, H. Nisell and K. Kublickiene (2004) The mechanism of EDHF-mediated responses in subcutaneous small arteries from healthy pregnant women. Am J Physiol Regul Integr Comp Physiol 286 R1102-R1109.
284. L.C. Kenny, P.N. Baker, D.A. Kendall, M.D. Randall and W.R. Dunn (2002) The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br J Pharmacol 136 1085-1088.
285. D.G.J. Martin, M.O. Gardner, L.A. Izquierdo, K. Tobey and L.B. Curet (1998) Incidence of intraventricular hemorrhage in neonates under 32 weeks of gestation delivered to mothers with severe pre-eclampsia. Prenat Neonat Med 3 250-254.
286. X. Xiong, L.D. Saunders, F.L. Wang, S.T. Davidge and P. Buekens (2001) Preeclampsia and cerebral palsy in low-birth-weight and preterm infants: implications for the current “ischemic model” of preeclampsia. Hypertens Pregnancy 20 1-13.
287. T.M. O'Shea, K.L. Klinepeter and R.G. Dillard (1998) Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol 147 362-369.